艾米卡辛在需要腎置換治療的重症患者中的使用:AMIDIAL-ICU研究
Vincent Dupont1,2, Bruno Mourvillier3,4, Coralie Barbe4
1Centre Hospitalier Universitaire de Reims, 45 rue Cognacq Jay, Reims, 51092, +33326787641, France. vdupont@chu-reims.fr.
Annals of intensive care
|March 26, 2025
概括
对于接受置换治疗的急性损伤患者来说,最佳的阿米卡辛剂量至关重要. 根据感染严重程度和透析类型,建议服用15-35mg/kg的剂量,以改善治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 密集护理医学 密集护理医学
背景情况:
- 急性损伤 (AKI) 在重症监护病房 (ICU) 普遍存在,往往需要置换疗法 (RRT).
- 对于接受RRT的AKI患者,阿米卡辛的最佳剂量策略仍未得到充分定义.
- 这种知识差距影响了重症患者的治疗疗效和安全性.
研究的目的:
- 为了确定需要RRT的AKI的ICU患者的最佳阿米卡辛剂量方案.
- 评估RRT模式和最小抑制度 (MIC) 对阿米卡辛药理学的影响.
- 为改善治疗药物监测提供基于证据的剂量建议.
主要方法:
- 一项前性观察性研究,涉及18家法国医院的111名成年ICU患者.
- 使用药理动力学建模来评估阿米卡辛的剂量方案,并模拟目标的实现.
- 收集的数据包括患者人口统计,RRT类型,阿米卡辛剂量和治疗药物监测结果.
主要成果:
- 持续的RRT和以前的慢性病被发现会降低阿米卡辛的透析清除.
- 对于MIC ≤ 4 mg/L,15 mg/kg的阿米卡辛在90%的间歇性透析患者中达到目标度;对于连续的RRT,需要20 mg/kg.
- 需要更高的剂量 (例如30 mg/kg) 才能达到MIC=8 mg/L的治疗目标.
结论:
- 目前在RRT的ICU患者的阿米卡辛监测实践往往不符合推的指南.
- 药理动力学建模确定了15-35毫克/千克的阿米卡辛剂量范围,根据MIC和透析方式量身定制.
- 这些发现支持个性化剂量,以优化阿米卡辛在这个脆弱患者群体中的有效性和安全性.
更多相关视频
07:03Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
Published on: February 15, 2022
1.4K
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
8.3K
相关概念视频
01:11Renal Failure: Dose Adjustments
50
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
50
01:17Factors Affecting Renal Clearance: Renal Impairment
44
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
44
01:27Dialysis
244
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
244
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
01:28Renal Drug Excretion: Tubular Secretion
100
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
100
01:15Drug Elimination by Renal Route: Tubular Secretion
2.1K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.1K